Sphera Funds Management’s Apellis Pharmaceuticals APLS Stock Holding History

Sphera Funds Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-214,914	Closed	-$8.65M	–	108
2026 Q1	$8.65M	Sell	214,914 -36,047	-14%	-$777K	1.37%	16
2025 Q4	$6.3M	Buy	250,961 +187,301	+294%	+$4.39M	1.22%	31
2025 Q3	$1.44M	Sell	63,660 -50,686	-44%	-$1.18M	0.3%	83
2025 Q2	$1.98M	Sell	114,346 -67,000	-37%	-$1.24M	0.46%	71
2025 Q1	$3.97M	Sell	181,346 -24,905	-12%	-$688K	0.91%	32
2024 Q4	$6.58M	Sell	206,251 -9,622	-4%	-$289K	1.19%	26
2024 Q3	$6.23M	Buy	+215,873	New	+$7.99M	0.99%	36
2019 Q1	–	Sell	-117,000	Closed	-$1.54M	–	110
2018 Q4	$1.54M	Sell	117,000 -95,470	-45%	-$1.46M	0.17%	81
2018 Q3	$3.78M	Buy	212,470 +101,667	+92%	+$1.88M	0.43%	69
2018 Q2	$2.44M	Buy	+110,803	New	+$2.55M	0.34%	78

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sphera Funds Management's APLS Position: Q2 2026 in Review

Sphera Funds Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 214,914 shares — an estimated $8.65M sold.

Sphera Funds Management first reported a position in APLS in Q2 2018 and held it in 10 quarters. The position peaked at $8.65M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Sphera Funds Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Sphera Funds Management sold 214,914 Apellis Pharmaceuticals shares in Q2 2026, an estimated $8.65M.
Sphera Funds Management first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 10 quarters.
Sphera Funds Management's Apellis Pharmaceuticals position peaked at $8.65M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.